Literature DB >> 6109538

Pharmacokinetics of the new beta-adrenoceptor blocking agent betaxolol (SL 75212) in man after repeated oral administration.

G Bianchetti, C Blatrix, R Gomeni, J R Kilborn, J Larribaud, P W Lücker, J J Thebault, S Trocherie, P L Morselli.   

Abstract

(+/-)-1-(Isopropylamino)-3-[p-(2-cyclopropyl-methoxyethyl)-phenoxy]-2-propanol HCl (betaxolol, SL 75212) was given to groups of healthy volunteers, 10 mg daily for 7 days followed by 20 mg daily 7 days in one group, and increasing daily doses up to 60 mg/day for a total of 15 days in the other group. The pharmacokinetics were studied during dosing and in the washout period. The pharmacokinetic characteristics were unchanged after repeated doses, T/2 16-22 h, Vd 7.7-8.8 l/kg; clearance 0.28-0.33 l/h/kg.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6109538

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  4 in total

1.  Time course of the bronchial response to salbutamol after placebo, betaxolol and propranolol.

Authors:  R Palminteri; G Kaik
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  Regeneration of beta-adrenergic receptors in senescent rats: a study using an irreversible binding antagonist.

Authors:  J Pitha; B A Hughes; J W Kusiak; E M Dax; S P Baker
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

3.  Pharmacokinetics of betaxolol in middle aged patients.

Authors:  G Bianchetti; J F Thiercelin; J P Thenot
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 4.  Betaxolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension.

Authors:  R Beresford; R C Heel
Journal:  Drugs       Date:  1986-01       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.